Galecto, Inc. (GLTO) Dividend History

Galecto, Inc. (GLTO) is a biotechnology company focused on developing and commercializing treatments for fibrosis and cancer. It specializes in small molecule therapeutics targeting galectin proteins, which play a role in various pathological processes. The company's therapies aim to address unmet medical needs in diseases characterized by fibrosis and tumor progression.

75 State Street, Boston, MA, 02109
Phone: 45-70-70-52-10
Website: https://www.galecto.com

Dividend History

Galecto, Inc. currently does not pay dividends

Company News

Galecto to Participate in Upcoming Investor Conferences

Galecto, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences, including the Oppenheimer 35th Annual Healthcare Life Sciences Conference, Leerink Partners Global Healthcare Conference, and 37th Annual ROTH Conference.

GlobeNewswire Inc.
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Galecto is focusing its pipeline on cancer and liver disease, leveraging its existing clinical-stage asset GB1211. The company has also acquired the global rights to BRM-1420, a novel dual inhibitor for multiple genetic subsets of acute myeloid leukemia (AML), from Bridge Medicines.

GlobeNewswire Inc.
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto’s GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinoma An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto’s GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinoma

GlobeNewswire Inc.
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research
New Strong Buy Stocks for February 14th

GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.

Zacks Investment Research

Featured Companies: LUMN SFST STOK

Dividend data last updated 06/07/2025 20:12:35 UTC